Targeted next‐generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. Issue 3 (July 2014)

• Record Type: Journal Article
• Authors: Amato, Eliana; Molin, Marco dal; Mafficini, Andrea; Yu, Jun; Malleo, Giuseppe; Rusev, Borislav; Fassan, Matteo; Antonello, Davide; Sadakari, Yoshihiko; Castelli, Paola; Zamboni, Giuseppe; Maitra, Anirban; Salvia, Roberto; Hruban, Ralph H; Bassi, Claudio; Capelli, Paola; Lawlor, Rita T; Goggins, Michael; Scarpa, Aldo
• Is Part Of: Journal of pathology. Volume 233:Issue 3(2014)
• Page Start: 217
• Page End: 227
• Publication Date: 2014-07
• Subjects: Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.4344
• Languages: English
• ISSNs: 0022-3417

Abstract

<abstract abstract-type="main" id="path4344-abs-0001"> <title>Abstract</title> <p id="path4344-para-0001">Intraductal neoplasms are important precursors to invasive pancreatic cancer and provide an opportunity to detect and treat pancreatic neoplasia before an invasive carcinoma develops. The diagnostic evaluation of these lesions is challenging, as diagnostic imaging and cytological sampling do not provide accurate information on lesion classification, the grade of dysplasia or the presence of invasion. Moreover, the molecular driver gene mutations of these precursor lesions have yet to be fully characterized. Fifty‐two intraductal papillary neoplasms, including 48 intraductal papillary mucinous neoplasms (IPMNs) and four intraductal tubulopapillary neoplasms (ITPNs), were subjected to the mutation assessment in 51 cancer‐associated genes, using ion torrent semiconductor‐based next‐generation sequencing. P16 and Smad4 immunohistochemistry was performed on 34 IPMNs and 17 IPMN‐associated carcinomas. At least one somatic mutation was observed in 46/48 (96%) IPMNs; 29 (60%) had multiple gene alterations. <italic>GNAS</italic> and/or <italic>KRAS</italic> mutations were found in 44/48 (92%) of IPMNs. <italic>GNAS</italic> was mutated in 38/48 (79%) IPMNs, <italic>KRAS</italic> in 24/48 (50%) and these mutations coexisted in 18/48 (37.5%) of IPMNs. <italic>RNF43</italic> was the third most commonly mutated gene and was always associated with <italic>GNAS</italic> and/or <italic>KRAS</italic> mutations, as were virtually all the low‐frequency mutations found in other genes. Mutations in <italic>TP53</italic> and <italic>BRAF</italic> genes (10% and 6%) were only observed in high‐grade IPMNs. P16 was lost in 7/34 IPMNs and 9/17 IPMN‐associated carcinomas; Smad4 was lost in 1/34 IPMNs and 5/17 IPMN‐associated carcinomas. In contrast to IPMNs, only one of four ITPNs had detectable driver gene (<italic>GNAS</italic> and <italic>NRAS</italic>) mutations. Deep sequencing DNA from seven cyst fluid aspirates identified 10 of the 13 mutations detected in their associated IPMN. Using next‐generation sequencing to detect cyst fluid mutations has the potential to improve the diagnostic and prognostic stratification of pancreatic cystic neoplasms. © 2014 The Authors. <italic>The Journal of Pathology</italic> published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</p> </abstract>